Skip to main content
. 2020 Sep 10;13(12):100865. doi: 10.1016/j.tranon.2020.100865

Fig. 3.

Fig. 3

M-MDSCs significantly decreased after anti-PD-1 therapy in PR group but not in SD and PD groups.

(A) The baseline levels of M-MDSCs in PR, SD, and PD groups. PR, N = 7; SD, N = 13; PD, N = 7. Two-tailed unpaired t-test was performed.

(B) The change of M-MDSCs levels in PR group after the first anti-PD-1 treatment, N = 7. Two-tailed paired t-test was performed.

(C) The change M-MDSCs levels with a consecutive dosage of anti-PD-1 therapy. X-axis: the cycles of anti-PD-1 treatment; Y-axis: M-MDSCs frequency. The number of dots of every cycle may be different because of the different follow-up duration of different patients. N = 7. Two-tailed paired t-test was performed between the baseline levels and any cycles of anti-PD-1 treatment.

ns: no significant difference, *p < 0.05, **p < 0.01 compared with the control group. A P value less than 0.05 was considered to be statistically significant.